Publication Year

Krelder ML, Unice KM, Panko JM. 2020. Human health risk assessment of tire and road wear particles (TRWP) in air. Hum Ecol Risk Assess 26(10):2567-2585; doi: 10.1080/10807039.2019.1674633.

Benson SM, Maskrey JR, Nembhard MD, Unice KM, Shirley MA, Panko JM. 2019. Evaluation of personal exposure to surgical smoke generated from electrocautery instruments: A pilot study. Ann Work Expos Health wxz070; open access.

Wikoff DS, Chappell GA, Fitch S, Doepker CL, Borghoff SJ. 2019. Lack of potential carcinogenicity for aspartame – Systematic evaluation and integration of mechanistic data into the totality of the evidence. Food Chem Toxicol 135:110866.

Ramírez-Valle F, Adams M, Beebe L, Chen J, Chuaqui C, Connarn JN, Corin AF, Dingley KH, et al. 2019. A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases. Abstract 1536, Annual Meeting of the American College of Rheumatology Conference, Atlanta, GA, November 2019.

Czerkies LM, Finn KL, Kineman BD, Reichert HA, Cohen SS, Carvalho RS. 2019. Use of a partially hydrolyzed 100% whey-based infant formula with Lacrobacillus reuteri in infants with caregiver-perceived intolerance. J Pedat Health Nutr, Open Access.

Marschke S, Rish W, Mauro J. 2019. Radiation exposures from the beneficial use of alumina production residue. J AWWA online.

Chappell GA, Borghoff SJ, Pham L, Doepker CL, Wikoff DS. 2019. Lack of potential carcinogenicity for sucralose — Systematic evaluation and integration of mechanistic data into the totality of the evidence. Food Chem Toxicol 135:110898.

Bylsma LC, Ording AG, Rosenthal A, Öztürk B, Fryzek JP, Arias JM, Röth A, Berentsen S. 2019. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Advances 3(20):2980–2985; doi:10.1182/bloodadvances.2019000476.

Thompson C, Chappell G, Cullen J, Wolf JC, Haws L. Development of an oral reference dose for GenX using the latest toxicological and risk assessment methodologies: Environmental risk assessment of per- and polyfluoroalkyl substances (PFAS). SETAC North America Focused Topic Meeting, Durham, NC, August 2019.

Chappell GA, Thompson CM, Wolf J, Cullen J, Haws LC. Transcriptomic responses in livers of GenX-treated mice demonstrate up-regulation of PPAR signaling and related pathways. Environmental Mutagenesis and Genomics Society, Washington, DC, September 2019.

Thompson CM. The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium. August 20, 2019.

Clewell RA, Thompson CM, Clewell HJ. 2019. Dose-dependence of chemical carcinogenicity: Biological mechanisms for thresholds and implications for risk assessment. Chem Biol Interact 301:112–127.

Chappell G, Rager J, Wolf J, Babic M, Leblanc, Ring C, Harris MA, Thompson CM. 2019. Comparison of gene expression responses in the small intestine of mice following exposure to three carcinogens using the S1500+ gene set informs a potential common adverse outcome pathway. Toxicol Pathol 47(7):851-864; doi: 10.1177/0192623319873.

van de Ligt J, Borghoff SJ, Yoon M, Ferguson LJ, DeMaio W, McClanahan RH. 2019. Nondetectable or minimal detectable residue levels of N-(n-butyl) thiophosphoric triamide in bovine tissues and milk from a 28-d NBPT dosing study. Translat An Sci 3(4).

Cekola P, Henrikson A, Reichert H, Cohen S, Huhmann M, Torres KA. Clinical use and safety of an amino acid-based infant formula in a real world setting. Poster at NASPGHAN, Chicago, IL, October 2019.

Bylsma LC, Dean R, Lowe K, Sangaré L, Alexander DD, Fryzek JP. 2019. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta‐analysis of patient and study characteristics. Cancer Med 8(12):5800–5809.

Hooda N, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. Poster presented at the Canadian Association for Pharmacy in Oncology Annual Conference, Halifax, NS, April 2019.

Hooda N, McFarlane T, Pasetka M, DeAngelis C. Chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer (CRC) patients undergoing FOLFOX Chemotherapy: A retrospective chart review comparing two Ontario hospitals. Abstract accepted for publication in J Pharmacy Pharmaceut Sci. Poster presented at the Canadian Society for Pharmaceutical Sciences Annual Conference, Vancouver, BC, May 2019.

Hooda N, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. J Oncol Pharmacy Prac (abstract 22), doi:10.1177/1078155219834495.

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024.